189 results on '"Fortpied, Catherine"'
Search Results
2. Acute toxicity in patients with oligometastatic cancer following metastasis-directed stereotactic body radiotherapy: An interim analysis of the E2-RADIatE OligoCare cohort
3. Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study
4. Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy: Real-world data from the E2-RADIatE OligoCare cohort
5. Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses
6. A Quality Control Study on Involved Node Radiation Therapy in the European Organisation for Research and Treatment of Cancer/Lymphoma Study Association/Fondazione Italiana Linfomi H10 Trial on Stages I and II Hodgkin Lymphoma: Lessons Learned
7. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group
8. Mapping the location of local and regional recurrences according to breast cancer surgery and radiation therapy: Results from EORTC 22922/10925
9. Reply to T. Vassilakopoulos et al
10. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis
11. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial
12. Using both clinical research and population-based cancer registry in long-term research- a case study using EORTC trials and the Dutch national cancer registry (IKNL)
13. Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma
14. Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses
15. Supplementary Data_Figures 1 from Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111)
16. Tables 3 from Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111)
17. Data from Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111)
18. Tables 2 from Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111)
19. Supplementary Data - "Tables 1" from Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111)
20. A Response to the Letter to the Editor: The Role of Personalization and Standardization in Stereotactic Body Radiation Therapy.
21. Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer
22. Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma.
23. Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111)
24. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
25. Evolution of Recurrent Asthma Event Rate over Time in Frailty Models
26. Rituximab maintenance improves overall survival of patients with follicular lymphoma—Individual patient data meta-analysis
27. The association of internal mammary and medial supraclavicular lymph node radiation technique with clinical outcomes
28. Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials
29. Relapse patterns in early‐PET negative, limited‐stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy–a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials
30. T001: FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial
31. High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline
32. High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: TMTV is a useful risk factor to stratify patients at baseline
33. The role of postoperative chemoradiation for oropharynx carcinoma: A critical appraisal revisited
34. Relapse patterns in early‐PET negative, limited‐stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy–a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials.
35. Diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma in the frail elderly: A phase II EORTC trial with a progressive and cautious treatment emphasizing geriatric assessment
36. Treatment patterns in older patients with locally advanced head and neck squamous cell carcinoma: Results from an EORTC led survey
37. A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial
38. Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients
39. Side effects 15 years after lymph node irradiation in breast cancer : randomized EORTC trial 22922/10925
40. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis
41. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group
42. Gem-(R)CHOP versus (R)CHOP: a randomized phase II study of gemcitabine combined with (R)CHOP in untreated aggressive non-Hodgkin’s lymphoma – EORTC lymphoma group protocol 20021 (EudraCT number 2004-004635-54)
43. Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials
44. Stage IIb High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response
45. Organ Preservation and Late Functional Outcome in Oropharyngeal Carcinoma: Rationale of EORTC 1420, the “Best of” Trial
46. Reference values for the EORTC QLQ‐C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors.
47. The Statistical Evaluation of Treatment and Outcomes in Head and Neck Squamous Cell Carcinoma Clinical Trials
48. Predictive Classifier for Intensive Treatment of Head and Neck Cancer
49. Prognostic Value of Immunohistochemical Markers in Stage III/IV Classical Hodgkin Lymphoma Treated Frontline in the Lysa EORTC 20012 Randomized Protocol
50. Predictive classifier for intensive treatment of head and neck cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.